Paratek Pharma Acquires Radius Health, Forms $1B Entity

In a significant move reshaping the specialty pharmaceutical sector, Paratek Pharmaceuticals has finalized its integration with Radius Health. This strategic combination establishes a robust, multi-product commercial enterprise poised to achieve an impressive $1 billion in annual revenue for 2026. The newly formed entity significantly broadens its therapeutic reach, now encompassing critical areas such as infectious diseases, podiatry, otolaryngology, allergy, rheumatology, endocrinology, and gynecology.

The cornerstone of this expanded platform is the addition of Radius Health's flagship osteoporosis treatment, TYMLOS (abaloparatide), to Paratek's existing commercial offerings, which include NUZYRA (omadacycline) for infectious diseases and XHANCE (fluticasone propionate) for respiratory conditions. This synergy allows for a more comprehensive approach to patient care across a wider spectrum of medical needs.

Financing for this transformative transaction was secured through substantial capital and debt facilities provided by a consortium of leading financial institutions. Key backers include B-FLEXION Life Sciences, which played a pivotal role, alongside significant contributions from Blackstone Credit & Insurance, Sixth Street, Oaktree Capital Management, Silver Point Capital, and Pharmakon Advisors. Wilmington Trust acted as the administrative agent for the financing.

Evan Loh, M.D., Chief Executive Officer of Paratek, highlighted the strategic importance of the merger, stating, "This combination represents a pivotal moment, creating a formidable specialty commercial platform with projected revenues nearing $1 billion. With the continued backing of B-FLEXION Life Sciences, we are strategically positioned to amplify the impact of our therapies and enhance value for patients and healthcare providers through the acquisition of further vital products."

The integration is expected to unlock significant commercial synergies. The osteoporosis market, for instance, is a substantial segment within the broader bone health sector, with global sales projected to grow steadily. TYMLOS, targeting postmenopausal women at high risk for fracture, addresses a critical unmet need, and its expanded market access through Paratek's established commercial infrastructure is a key growth driver.

Nithya Desikan, Operating Partner at B-FLEXION Life Sciences, emphasized the strategic rationale, noting, "The combined Paratek platform, fortified by B-FLEXION Life Sciences' resources and Paratek's demonstrated commercial acumen, is set to deliver exceptional value. Radius has made remarkable strides in establishing TYMLOS as a vital treatment, and we are eager to build upon this success and explore new market opportunities for the therapy."

Legal counsel for Paratek was provided by Skadden, Arps, Slate, Meagher & Flom LLP, while Lazard served as the financial advisor. This strategic consolidation underscores a trend within the pharmaceutical industry towards building diversified portfolios and leveraging existing commercial infrastructure to maximize the value of innovative therapies.